NurseJet
Back to Discover
Research ArticleResearchMedication SafetyPatient Education

OM-85 did not prevent preschool wheezing illness in the ORBEX trial

Lancet (PubMed)Sep 19, 2026

AI-summarized from the linked source. Educational brief, not medical advice.

Brief summary

In a double-blind randomized trial of infants at increased risk for asthma, two years of oral OM-85 did not delay or reduce the first wheezing lower respiratory tract illness during the following three years compared with placebo.

What NurseJet pulled from the source

The ORBEX trial randomized 822 children aged 6 to 18 months. During the off-treatment observation period, wheezing illness occurred in 71 of 342 children in the OM-85 group and 61 of 339 in the placebo group (HR 1.16; 95% CI 0.82 to 1.64), with no significant difference in the primary outcome.

Why this matters for nurses

Families of young children at elevated asthma risk may ask about products promoted to prevent future wheezing. This large trial does not support presenting OM-85 as an effective primary-prevention strategy for asthma-like symptoms in this population.

Bedside takeaway

Do not present OM-85 as proven prevention for preschool wheezing; reinforce the child's prescribed respiratory plan instead.

Key takeaways

  • Children received OM-85 or placebo for 10 days each month over 24 months, followed by 36 months of observation off treatment.
  • The trial did not find a significant difference in time to first wheezing lower respiratory tract illness during observation.
  • Fevers, coughs, and colds were the most frequent adverse events and did not differ between groups.

Practice implications

  • Use the child's prescribed wheeze or asthma action plan for symptom recognition and escalation, and avoid suggesting bacterial lysate products as proven primary prevention. Direct product questions to the pediatric clinician and follow local respiratory-care protocols.

Limitations & cautions

  • The trial enrolled children with selected asthma-risk factors at 11 U.S. academic sites, and 596 of 822 randomized children completed the full observation period. The result addresses OM-85 for primary prevention in this population, not treatment of established asthma or acute wheezing.
  • AI-summarized from the linked source. Review the original article before applying to practice.

Citations

Exact source links

Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.

Lancet (PubMed)

Lancet (PubMed). Use of the bacterial lysate OM-85 for the primary prevention of wheezing lower respiratory illness in preschool children: a randomised, placebo-controlled trial.

Open original source

https://pubmed.ncbi.nlm.nih.gov/42705251/

Professional education only

This summary does not replace clinical judgment, facility policy, provider orders, or official guidelines. Verify practice changes against the original source and local protocol.

Related briefs

More updates for this clinical area

Back to Discover

Family Medicine and Community Health (PubMed)

A dose-response meta-analysis of prospective cohorts found that higher ultra-processed food intake was associated with higher risks of cardiovascular events, cancer, obesity or overweight, metabolic syndrome or diabetes, depression or anxiety, digestive disease, and all-cause mortality.

Med-SurgTelemetryAI summaryReview source

Journal of Clinical Nursing (PubMed)

A mixed-methods systematic review found that nurses viewed situational awareness, teamwork, communication, leadership, experience, intuition, and freedom from retribution as important to recognizing and escalating clinical deterioration.

LeadershipMed-SurgAI summaryReview source

Journal of Advanced Nursing (PubMed)

A systematic review and meta-analysis found moderate-certainty evidence that nurse-led or nurse-coordinated multicomponent nonpharmacologic programs reduced delirium incidence in hospitalized adults aged 60 or older.

GeriatricsMed-SurgAI summaryReview source